InterCure Ltd. (NASDAQ:INCR - Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 13,000 shares, an increase of 21.5% from the April 30th total of 10,700 shares. Based on an average daily volume of 14,900 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.1% of the company's stock are short sold.
InterCure Trading Up 2.0%
Shares of NASDAQ:INCR traded up $0.03 on Friday, hitting $1.50. 1,546 shares of the company traded hands, compared to its average volume of 27,346. The stock has a 50 day simple moving average of $1.47 and a 200-day simple moving average of $1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.78 and a quick ratio of 1.15. InterCure has a 52 week low of $1.17 and a 52 week high of $2.62.
Hedge Funds Weigh In On InterCure
A hedge fund recently bought a new stake in InterCure stock. Moore Capital Management LP acquired a new position in InterCure Ltd. (NASDAQ:INCR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 97,273 shares of the company's stock, valued at approximately $156,000. Moore Capital Management LP owned approximately 0.21% of InterCure at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.34% of the company's stock.
About InterCure
(
Get Free Report)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Further Reading
Before you consider InterCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.
While InterCure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
